Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of OC-01 (Varenicline) Nasal Spray vs Oral Varenicline
NCT04072146Phase 1Completed
- Sponsor
- Oyster Point Pharma
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varenicline in dry eye disease (DED) (2 arms), sponsored by Oyster Point Pharma. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 120 hours, Area Under the Concentration-Time Curve From Time Zero to Infinity at 120 hours and 2 more. Started Aug 2019; status: completed.
02
Drugs
varenicline
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04072146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072146.